Clinical trials: Oral Phase
Healthy Volunteers
A Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-DNL343 Following a Single Oral Dose in Healthy Male Participants
This is a Phase 1, open-label, nonrandomized, single-dose study in healthy male participants to investigate the absorption, metabolism and excretion of DNL343.
- Trial name
- NCT06281158
- Testing
- [14C]-DNL343
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Denali Therapeutics Inc.
Small Cell Lung Cancer
A Dose Finding and Expansion Study of RO7051790 Administered Orally in Participants With Relapsed, Extensive-Stage Disease Small Cell Lung Cancer (ED SCLC)
This is a Phase I, open-label, multicenter study designed to assess the safety and tolerability of RO7051790 in participants with relapsed ED SCLC.
- Trial name
- NCT02913443
- Testing
- RO7051790
- Where
- 8 sites in United States, Canada and 3 more
- Volunteers
- 18 people
- Sponsor
- Hoffmann-La Roche
Healthy
Clinical Trial to Assess Pharmacodynamic Effects on Segmental Endotoxin Induced Inflammatory Response of BI 1026706 Versus Placebo
The primary and secondary objectives of the current study are the assessments of anti-inflammatory pharmacodynamic effects on segmental endotoxin induced inflammatory response after 4 weeks treatment with BI 1026706.
- Trial name
- NCT02657408
- Testing
- BI 1026706
- Where
- Germany
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Schizophrenia
A Study to Evaluate Multiple Oral Doses of Luvadaxistat in Adults With Schizophrenia
The purpose of this study is to determine whether luvadaxistat is superior to placebo in improving cerebellar function as measured with the average percentage of conditioned responses during the eyeblink conditioning (EBC) test.
- Trial name
- NCT03359785
- Testing
- Luvadaxistat
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Neurocrine Biosciences
Neuroendocrine Tumors, Pancreatic Neuroendocrine Tumor
Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors
CVM-1118 (TRX-818) is a new small molecule chemical entity being developed as a potential anti-cancer therapeutic by TaiRx, Inc. CVM-1118 is a potent anti-cancer agent in numerous human cancer cell lines.
- Conditions
- Neuroendocrine Tumors, Pancreatic Neuroendocrine Tumor, Gastro-enteropancreatic Neuroendocrine Tumor, Lung Neuroendocrine Neoplasm
- Trial name
- NCT03600233
- Testing
- CVM-1118
- Where
- 8 sites in Taiwan
- Volunteers
- 34 people
- Sponsor
- TaiRx, Inc.
Heterozygous Familial Hypercholesterolemia
Study to Assess the Efficacy and Safety of LIB003 in HeFH Patients on Oral Lipid Therapy Needing Further LDL-C Reduction
This study is to assess LDL-C reductions at Week 24 and the mean of Weeks 22 and 24 with monthly Q4W (≤31 days) dosing of LIB003 300 mg administered subcutaneously (SC) compared to placebo in patients 18 years or older with…
- Trial name
- LIBerate-FH (NCT04797104)
- Testing
- lerodalcibep
- Where
- 7 sites in United States, Israel and 3 more
- Volunteers
- 478 people
- Sponsor
- LIB Therapeutics LLC
Healthy Subjects
Drug-drug Interactions Between AZD4205 and Itraconazole/Carbamazepine
This is a Phase 1, single-center, nonrandomized, open-label, 2-part, fixed-sequence, drug-drug interaction (DDI) study to assess the effect of multiple doses of itraconazole, a CYP3A4 enzyme inhibitor, on the single dose PK of…
- Trial name
- NCT05486949
- Testing
- AZD4205 and carbamazepine, AZD4205 and itraconazole
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Dizal Pharmaceuticals
Irritable Bowel Syndrome
A Multi-Center Trial to Determine the Safety and Efficacy of LX1033 in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome
The objective of this study is to evaluate the safety and efficacy of LX1033 over a range of dose levels in subjects with diarrhea-predominant Irritable Bowel Syndrome (IBS).
- Trial name
- NCT01494233
- Testing
- 250 mg LX1033 tablets
- Where
- 81 sites in United States
- Volunteers
- 373 people
- Sponsor
- Lexicon Pharmaceuticals
Bipolar I Disorder
A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Subjects With Bipolar I Disorder
The goal of this clinical trial is to assess the safety and effects of a crystallized form of lithium, AL001, when compared to commonly used lithium carbonate in individuals diagnosed with bipolar I disorder.
- Trial name
- NCT07540338
- Testing
- AL001, Lithium carbonate
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Alzamend Neuro, Inc.
Multiple Myeloma
A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT)
The purpose of this study is to determine the effect of ixazomib maintenance therapy on progression free survival (PFS) compared with placebo, in participants with NDMM who have had a major response (complete response [CR], very…
- Trial name
- NCT02312258
- Testing
- Ixazomib
- Where
- 275 sites in United States, Argentina and 33 more
- Volunteers
- 706 people
- Sponsor
- Takeda
KCNT1-Related Epilepsy
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ABS-1230 Given Orally Compared With Placebo in Healthy Participants Aged 18 to 55 Years
This first in human trial will evaluate the safety, tolerability, and pharmacokinetics of single ascending doses, multiple ascending doses, and fed and fasted doses of ABS-1230 given orally compared with placebo in adult healthy…
- Trial name
- NCT07156201
- Testing
- ABS-1230, Omeprazole, Voriconazole
- Where
- Australia
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Actio Biosciences, Inc.
Uterine Fibroids, Heavy Menstrual Bleeding
Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids
The primary objective of this study is to demonstrate the superior efficacy versus placebo of OBE2109 alone and in combination with add-back therapy for the reduction of heavy menstrual bleeding associated with uterine fibroids…
- Trial name
- PRIMROSE 1 (NCT03070899)
- Testing
- OBE2109, Add-back
- Where
- 116 sites in United States
- Volunteers
- 526 people
- Sponsor
- ObsEva SA
Healthy Adults
A Study to Determine the Effect of KP-001 on Metformin and Midazolam Pharmacokinetics and the Effect of Clarithromycin on KP-001 Pharmacokinetics in Healthy Adult Participants
The purpose of this study is to determine the Effects of KP-001 on Metformin (a substrate of MATE1) and Midazolam (a substrate of CYP3A4) Pharmacokinetics and the Effect of Clarithromycin (potent CYP3A4/P-gp Inhibitor) on KP-001…
- Trial name
- NCT06227832
- Testing
- KP-001, Metformin, Midazolam
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Kaken Pharmaceutical
Myocardial Infarction
Firibastat or Ramipril After Acute Myocardial Infarction for Prevention of Left Ventricular Dysfunction
This is a multicenter, randomized, double-blind, active-controlled, dose-titrating phase 2 study to evaluate the safety and efficacy of firibastat administered orally BID (2 daily doses) versus ramipril administered orally BID…
- Trial name
- QUORUM (NCT03715998)
- Testing
- Ramipril, Firibastat
- Where
- 7 sites in France, Germany and 5 more
- Volunteers
- 295 people
- Sponsor
- Quantum Genomics SA
Type 2 Diabetes Mellitus
Study of Two Oral Formulations of LX4211 in Patients With Type 2 Diabetes Mellitus
This protocol is intended to compare the effects of both a solid (tablet) and liquid oral dosage form of LX4211 in subjects with type 2 diabetes mellitus.
- Trial name
- NCT01188863
- Testing
- 300 mg LX4211 (150 mg tablets), 300 mg LX4211 (50 mg tablets), 300 mg LX4211 (liquid)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Lexicon Pharmaceuticals
Obesity
A Study to Evaluate the Effect of the Experimental GLP-1 Drug PF-07081532 on Blood Levels of Common Birth Control Pills, and Drugs Omeprazole and Midazolam, and Effect of GLP-1 Drug Semaglutide on Midazolam Blood Levels in Healthy Adults With Weight in the Obesity Range
Two different groups of healthy volunteers will be chronically treated with GLP-1 drugs PF-07081532 or alternatively Semaglutide.
- Trial name
- NCT05671653
- Testing
- PF-07081532, Semaglutide
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Pfizer
Measles, Mumps
A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Given to Healthy Children 4 to 6 Years of Age
The purpose of this study is to evaluate how consistently 3 different manufacturing lots of the GSK's investigational measles, mumps, rubella, and varicella (MMRVNS) vaccine will produce an immune response.
- Conditions
- Measles, Mumps, Rubella, Varicella (Chickenpox)
- Trial name
- MMRVNS 20-002 (NCT07742644)
- Testing
- MMRVNS vaccine, MMRV vaccine, DTaP-IPV vaccine
- Where
- 62 sites in United States, Argentina and 4 more
- Volunteers
- 1,860 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Non Hodgkin Lymphoma, Richter Transformation
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
This is a Phase 1, multi-center, open-label study with a dose-escalation phase (Phase 1a) and a cohort expansion phase (Phase 1b), to evaluate the safety, tolerability, and PK profile of LP-118 under a once daily oral dosing…
- Conditions
- Non Hodgkin Lymphoma, Richter Transformation, Multiple Myeloma, T-cell-prolymphocytic Leukemia
- Trial name
- NCT04771572
- Testing
- LP-118
- Where
- 8 sites in United States
- Volunteers
- 100 people
- Sponsor
- Newave Pharmaceutical Inc
Asthma
A Study of Lebrikizumab (RO5490255) in Participants With Severe Oral Corticosteroids (OCS) Dependent Asthma
This randomized, multicenter, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy of lebrikizumab compared with placebo, as measured by the ability of participants to achieve lower daily doses of…
- Trial name
- NCT01987492
- Testing
- Lebrikizumab
- Where
- 71 sites in United States, Australia and 14 more
- Volunteers
- 230 people
- Sponsor
- Hoffmann-La Roche
Solid Tumors
Phase I Study of BAY1436032 in IDH1-mutant Advanced Solid Tumors
The primary objective of this study is: Determine the safety, tolerability, maximum tolerated dose (MTD) or recommended Phase II dose (RP2D) of BAY 1436032 in patients with isocitrate dehydrogenase-1 (IDH1)-R132X-mutant advanced…
- Trial name
- NCT02746081
- Testing
- BAY1436032
- Where
- 13 sites in United States, Denmark and 2 more
- Volunteers
- 81 people
- Sponsor
- Bayer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.